Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

The EAU 2026 CAPTAIN study presentation will be given by Laurence Klotz, CM, MD, FRCSC, an esteemed urologist, a professor of surgery at the University of Toronto, the Sunnybrook Chair of Prostate ...
Seeking Alpha

Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Seeking Alpha

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound ...
Taiwan News

Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...
manilatimes

PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound” or the "Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
The Bakersfield Californian

PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to ...

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 earnings call transcript

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...
manilatimes

Profound Medical Honored with INOVAIT’s 2025-2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound” or the "Company”), a commercial-stage innovator in interventional MRI ("iMRI”) procedures, is ...
Mena FN

PRO FAMILIA And Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access To Incision-Free Care For Women's Health

(MENAFN- GlobeNewsWire - Nasdaq) Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound ...